Pasithea Therapeutics (KTTA) Depreciation & Amortization (CF) (2022 - 2025)
Pasithea Therapeutics (KTTA) posted Depreciation & Amortization (CF) of -$421.0 for Q4 2025, down 101.75% sequentially from $24000.0 in Q3 2025, and down 108.68% YoY from $4852.0 in Q4 2024.
Pasithea Therapeutics (KTTA) Depreciation & Amortization (CF) (2022 - 2025) Analysis & Trends
Pasithea Therapeutics has reported Depreciation & Amortization (CF) for 4 years, with the latest figure at -$421.0 in Q4 2025.
- Quarterly Depreciation & Amortization (CF) fell 108.68% year-over-year to -$421.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $27579.0 (up 40.19% YoY) and the FY2025 annual result came in at $32000.0, up 68.42% from the prior year.
- Depreciation & Amortization (CF) fell to -$421.0 in Q4 2025 per KTTA's latest filing, from $24000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $24000.0 in Q3 2025 and troughed at -$421.0 in Q4 2025.
- A 4-year average of $6679.2 and a median of $4769.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The widest YoY moves for Depreciation & Amortization (CF): up 380.0% in 2025, down 108.68% in 2025.
- Over 4 years, Depreciation & Amortization (CF) stood at $4138.0 in 2022, then rose by 13.1% to $4680.0 in 2023, then advanced by 3.68% to $4852.0 in 2024, then plunged by 108.68% to -$421.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered -$421.0, $24000.0, and $4000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -421.00 |
| Dec 31, 2025 | -421.00 |
| Sep 30, 2025 | 24,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,821.00 |
| Mar 31, 2025 | 4,821.00 |
| Dec 31, 2024 | 4,852.00 |
| Dec 31, 2024 | 4,852.00 |
| Sep 30, 2024 | 5,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 4,717.00 |
| Mar 31, 2024 | 4,717.00 |
| Dec 31, 2023 | 4,680.00 |
| Dec 31, 2023 | 4,680.00 |
| Sep 30, 2023 | 4,715.00 |
| Sep 30, 2023 | 4,715.00 |